The UK has long been a world leader for clinical trials and life sciences research. But after losing ground post-COVID and post-Brexit, the country has begun to rethink the landscape for clinical trials. In this free New Scientist podcast, we meet the chair of the UK review into commercial clinical trials, James O'Shaughnessy, and ask how the independent review has influenced the reinvention of the clinical trials infrastructure for a new age of medicine.

Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency

Hosted on Acast. See acast.com/privacy for more information.

Learn more about your ad choices. Visit megaphone.fm/adchoices